MYCN and prostate carcinoma: AR expression in normal prostate tissues may inhibit CHRM4 expression; however, AR inhibition in advanced prostate cancer after ADT may lead to CHRM4/AKT/MYCN activation, which in turn promotes the NED and invasiveness of prostate cancer cells.